Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 7Stomach Neoplasms 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Hodgkin Disease 2Glioblastoma 2mCRPC 1Uterine Cervical Neoplasms 1Unresectable Stage III Non-small Cell Lung Cancer 1Tongue Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Rare Tumour 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1MSI-H Colorectal Cancer 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × tislelizumab × Clear all
NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡